Trial Profile
Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently With Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 19 Oct 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Cisplatin (Primary)
- Indications Adenocarcinoma; Cervical cancer; Squamous cell cancer
- Focus Therapeutic Use
- 23 Sep 2023 Planned End Date changed from 23 May 2024 to 21 Sep 2024.
- 26 Jun 2023 Planned End Date changed from 23 May 2023 to 23 May 2024.
- 24 May 2022 Planned End Date changed from 1 May 2022 to 23 May 2023.